Latest disclosed round
Series B
- Date
- 2022-06-01
- Amount
- USD 97m
- Sector
- Biotech & techbio
- Companies House
- 11609215
Series B
MiroBio
Immunology (checkpoint agonists, autoimmune disease)
CandidateSeries BOxford
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
7 linked investors
Funding record
2 disclosed rounds
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2022-08-04 | Acquisition | $405M | Gilead Sciences, Inc. (acquirer) |
| 2022-06-01 | Series B | $97M | not specified in source, Oxford Science Enterprises, Samsara BioCapital, SR One, Medicxi, Advent Life Sciences, OrbiMed, Monograph |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.